Home > Boards > US OTC > Biotechs >

Taxus Cardium Pharmaceuticals Group Inc. (CRXM)

CRXM RSS Feed
Add CRXM Price Alert      Hide Sticky   Hide Intro
Moderator: docj
Search This Board: 
Last Post: 5/20/2022 6:14:52 AM - Followers: 123 - Board type: Free - Posts Today: 1


https://genebiotherapeutics.com/

For filings:https://genebiotherapeutics.com/investors/


Investment by Nostrum Pharmaceuticals LLC: https://www.otcmarkets.com/filing/html?id=14182106&guid=TmVFUWUD04P0tth

On August 2, 2021, the Audit Committee approved the appointment of RAM Associates, LLP (“RAM Associates”) as our new independent registered public accounting firm, effective immediately, to perform independent audit services for the fiscal years ending December 31, 2021 and 2020. RAM Associates has served as the auditor for Nostrum Laboratories, Inc. and its affiliates, which are subsidiaries of Nostrum Pharmaceuticals LLC, our largest shareholder, since 2008.


Clinicaltrials.com update:
https://clinicaltrials.gov/ct2/show/NCT02928094?term=generx&rank=1


Understanding refractory angina and the AFFIRM study:
https://www.myrefractoryangina.com/




Taxus Cardium Announces Name Change To Gene Biotherapeutics

January 10, 2018PR-M01-18-NI-021

 

SAN DIEGO, Jan. 8, 2018 /PRNewswire/— Taxus Cardium Pharmaceuticals Group (Trading Symbol: CRXM) today announced plans to affect a name change from Taxus Cardium Pharmaceuticals Group Inc. to Gene Biotherapeutics Inc. 

The name change reflects the Company's plan to exclusively focus on the late-stage clinical research and commercialization of gene-based biotherapeutics for niche markets in the oncology and cardiology spaces for patients with unmet medical needs.  Gene Biotherapeutics is actively pursuing the acquisition of clinical development and commercialization rights to new and innovative, late-stage, DNA-based product opportunities focused on multiple forms of cancer to leverage the company's established and validated adenovector-based technology platform and deep experience in the clinical advancement and commercialization of gene therapy product candidates.

Previously, the Company established Angionetics Inc., an 85% majority-owned subsidiary, to lead Gene Biotherapeutics' cardiovascular clinical research and commercialization activities.  Angionetics is currently focused on independent financings to support advancement of the FDA-cleared, Generx AFFIRM Phase 3 clinical study of patients with refractory angina (myocardial ischemia) due to advanced coronary artery disease. There are an estimated 1.0 million patients with refractory angina in the United States. Gene Biotherapeutics' plan to advance forward to establish Angionetics as an independent company remains unchanged.  As previously reported, Gene Biotherapeutics expects to retain a substantial long-term equity investment in Angionetics following completion of the planned external financings. For more information about the Generx AFFIRM Phase 3 clinical study visit www.MyRefractoryAngina.com.

Angionetics is also considering the initiation of multiple Phase 2 clinical studies to evaluate the Generx angiogenic gene therapy product candidate as a treatment for patients with Cardiac Syndrome X (microvascular dysfunction) and certain forms of congestive heart failure, including ischemic cardiomyopathy.

Angionetics' Generx [Ad5FGF-4] is a first in class, disease altering, one-time administered, late-stage, angiogenic gene therapy product candidate which has been biologically engineered to enhance blood flow (perfusion) in ischemic regions of the heart by leveraging cardiac plasticity to promote the natural formation and growth of microvascular coronary structures (collateral vessels). This is achieved by stimulating and augmenting the heart's innate natural capacity to modulate the enlargement of pre-existing collateral arterioles (arteriogenesis), and to form new capillary vessels (angiogenesis) in select ischemic regions downstream from large coronary arteries.

Angionetics is being uniquely positioned to become a leading molecular interventional cardiology company, and is seeking to develop a portfolio of new and innovative, single-treatment, gene-based, catheter-administered therapeutic products focused on the biologic modulation of cardiac conductivity, contraction and angiogenic revascularization to address the global unmet medical needs of millions of patients with multiple forms of heart disease. Consistent with Angionetics' business strategy, the company is currently considering the acquisition of several early-stage gene therapy product candidates.  To learn more about Angionetics visit www.angionetics.com.

As previously reported, Gene Biotherapeutics further plans to monetize its FDA-cleared, U.S.-patented, Excellagen, a highly-purified, aseptically-manufactured, fibrillar bovine collagen [2.6%] flowable dermal matrix for the treatment of diabetic neuropathic lower extremity ulcers, pressure and venous ulcers as well as other wound healing applications.  Excellagen has demonstrated its medical utility as a delivery platform for stem cells, and also carries the potential as a topical dermal delivery vehicle for small molecule drugs, peptides, proteins, and exosomes.   Excellagen® has been designated as a skin substitute (bearing a unique product Q Code), in accordance with the standards established by the U.S. Centers for Medicare and Medicaid Services (CMS). For more information about Excellagen, visit https://www.youtube.com/watch?v=D2GYCYc_8JE.

As of December 31, 2017, approximately 14.3 million shares of Gene Biotherapeutics Common Stock were issued and outstanding, and approximately 4.6 million additional shares of Common Stock have been reserved for future issuance upon the conversion of the Series A Convertible Preferred Stock.

 
CRXM
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CRXM News: Amended Annual Report (10-k/a) 04/14/2022 02:10:58 AM
CRXM News: Annual Report (10-k) 03/30/2022 01:27:45 PM
PostSubject
#5301  Sticky Note CEO email 9/25/21 re:filings docj 09/25/21 08:06:15 AM
#5740   I would not hold my breath. They have lakes 05/20/22 06:14:52 AM
#5739   Super pathetic that a company that has assets BlackSnake1 05/19/22 03:21:56 PM
#5737   When not trading and zero real news, I BlackSnake1 05/06/22 05:10:24 PM
#5736   docj.....For Sure We Need To See The Complete Picture bentleyt 05/06/22 11:55:53 AM
#5735   Seems to me the subsequent quarter filings from docj 05/06/22 07:52:53 AM
#5734   My sense is they may have the quarters marketmanallm 05/06/22 07:49:06 AM
#5733   Totally inexcusable not to have this ticker trading BlackSnake1 05/05/22 04:24:42 PM
#5732   docj.....All in the works....IMHO SOON bentleyt 05/03/22 11:38:20 PM
#5731   It would be nice to get notice a docj 05/02/22 07:03:37 PM
#5730   One good thing about this ticker is its _fatty_ 04/29/22 03:45:09 PM
#5729   How is this relevant in 2022? Tia, campe 04/27/22 02:42:19 PM
#5728   $CRXM: This is now ANGIONETICS ???? makinezmoney 04/27/22 11:22:06 AM
#5727   docj....thanks! bentleyt 04/19/22 04:06:43 PM
#5726   EXPLANATORY NOTE TO 10-K/A docj 04/19/22 10:37:32 AM
#5725   docj.....What was the 10-K amendment about? bentleyt 04/19/22 10:10:50 AM
#5724   "We intend to become current" ..I believe marketmanallm 04/15/22 04:05:49 PM
#5723   One of my biggest loser here, I still vinsterr 04/14/22 11:36:32 AM
#5722   Every time they file its that sentence "we marketmanallm 04/14/22 09:33:17 AM
#5721   Yep, gettin’ there. Slowly… Gnarlyman 04/14/22 07:01:18 AM
#5720   10K was ammended docj 04/14/22 06:38:39 AM
#5719   All of the rest of filings do not BlackSnake1 04/06/22 02:48:08 PM
#5718   so now we have all of 2021 filings i_like_bb_stock 04/05/22 01:18:53 PM
#5717   I was confident that JJ and Bentley were _fatty_ 04/04/22 10:51:47 AM
#5716   Ks take longer to file, it's just the crazyflavor 03/31/22 02:14:59 PM
#5715   I would expect 2021 Fins to be much campe 03/31/22 01:42:57 PM
#5714   JJ24.....Nostrum Has Annual Sales Over $200 Million A bentleyt 03/31/22 11:07:49 AM
#5713   You would think the $3.8 million ,the funding JJ24 03/31/22 10:34:51 AM
#5712   the legal section of latest SEC filing shows marketmanallm 03/31/22 10:09:26 AM
#5711   That would be nice. I scanned through the lakes 03/31/22 10:04:08 AM
#5710   I believe its about buying time to secure marketmanallm 03/31/22 09:33:04 AM
#5709   So 4 more Qs and 1 K for Gnarlyman 03/30/22 09:13:26 PM
#5708   docj.....Nostrum Has Invested Several $Million Dollars Along With bentleyt 03/30/22 09:01:05 PM
#5707   Maybe this allows for speeding up the process. docj 03/30/22 07:35:56 PM
#5706   docj.....Thanks real progress.....Look forward to more good news bentleyt 03/30/22 07:08:27 PM
#5705   https://s3.amazonaws.com/sec.irpass.cc/2452/0001493152-22-008205.htm docj 03/30/22 06:43:09 PM
#5704  Restored I don't get you. You are unhappy when _fatty_ 03/23/22 01:46:21 PM
#5703   Child JJ24 03/23/22 01:42:11 PM
#5702   Regardless of the position size VERY Optimistic about _fatty_ 03/23/22 01:40:15 PM
#5701   Ram never promised me anything. Stop referring to JJ24 03/23/22 01:31:06 PM
#5700  Restored But RAM promised you and Zaporozhets "timely fashion" _fatty_ 03/23/22 01:09:28 PM
#5699   Means I’m close to a year of holding Gnarlyman 03/23/22 10:39:02 AM
#5698   What’s up Doc? Just trying my best to JJ24 03/23/22 10:36:20 AM
#5697   now that's funny !!! marketmanallm 03/23/22 10:14:45 AM
#5696  Restored 50 million in real estate _fatty_ 03/23/22 09:52:00 AM
#5695   Again I'll reiterate,,, No one knows anything here marketmanallm 03/23/22 07:10:22 AM
#5694   Right On! Good to Hear! BlackSnake1 03/22/22 09:24:04 PM
#5693   Bentley and JJ have insider info knowledge. They _fatty_ 03/22/22 06:50:54 PM
#5692   Looks like they played everybody. No trading symbol, BlackSnake1 03/22/22 06:09:37 PM
#5691   who played who ??....Nostrum has 2 mill marketmanallm 03/22/22 05:25:29 PM
#5690   They played everybody and now shareholders have worthless BlackSnake1 03/22/22 04:07:00 PM
PostSubject
Consent Preferences